Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rincell-1 Otic Neural Progenitor Cell-Based Therapy in Adults With Neural Hearing Loss
NCT07032038Phase 2Not yet recruiting
- Sponsor
- Rinri Therapeutics
- Start
- Sep 2027
- Primary completion
- May 2029
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of Rincell-1 in sensorineural hearing loss (SNHL), presbycusis, auditory neuropathy (ANSD), sponsored by Rinri Therapeutics. Planned start Sep 2027; status: not yet recruiting.
02
Drugs
Rincell-1
03
Conditions
sensorineural hearing loss (SNHL)presbycusisauditory neuropathy (ANSD)
Beyond the preview
Go deeper on NCT07032038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07032038.